Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Medicaid Add-On Rebates For Line Extensions Remain A Judgment Call

This article was originally published in The Pink Sheet Daily

Executive Summary

Manufacturers must continue to use their discretion on which line extensions should be subject to inflation-based Medicaid rebates in lieu of guidance from CMS in its recent AMP final rule.


Related Content

Abuse-Deterrent Exemption From Medicaid Rebates Hinges On FDA Standards
Manufacturers Seek CMS Definition Of “Specialty Pharmacy”
Manufacturers See AMP Rule’s “Presumed Inclusion” Proposal As Certainly Challenging
AMP Rule Answers Questions On Collecting Pricing Data For “5i” Specialty Drugs Raised By Manufacturers